{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "b382600f",
   "metadata": {},
   "source": [
    "# Tabla de medicamentos huérfanos extraida de EMEA."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "33264711",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "Medicine name",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "Related EMA product number",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "Active substance",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "Date of designation / refusal",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "Intended use",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "EU designation number",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "Status",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "First published date",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Last updated date",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "Orphan designation URL",
         "rawType": "object",
         "type": "string"
        }
       ],
       "conversionMethod": "pd.DataFrame",
       "ref": "ba0323f2-0ec4-47e6-aa0c-7828ac8086a9",
       "rows": [
        [
         "8",
         null,
         null,
         "Rilzabrutinib",
         "16/01/2025",
         "Treatment of autoimmune haemolytic anaemia",
         "EU/3/24/3019",
         "Positive",
         "20/02/2025",
         null,
         "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3019"
        ],
        [
         "9",
         null,
         null,
         "Clofutriben",
         "16/01/2025",
         "Treatment of Cushing's syndrome of endogenous origin",
         "EU/3/24/3024",
         "Positive",
         "20/02/2025",
         null,
         "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3024"
        ],
        [
         "10",
         null,
         null,
         "xevinapant",
         "11/11/2015",
         "Treatment of ovarian cancer",
         "EU/3/15/1576",
         "Withdrawn",
         "06/01/2016",
         "20/02/2025",
         "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1576"
        ],
        [
         "11",
         null,
         null,
         "Adeno-associated virus serotype 5 vector encoding C1-esterase inhibitor",
         "10/11/2022",
         "Treatment of hereditary angioedema",
         "EU/3/22/2722",
         "Withdrawn",
         "23/01/2023",
         "20/02/2025",
         "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2722"
        ],
        [
         "12",
         null,
         null,
         "Autologous CD34+ cells transfected with lentiviral vector containing the Wiskott-Aldrich syndrome protein gene (etuvetidigene autotemcel)",
         "07/10/2013",
         "Treatment of Wiskott-Aldrich syndrome",
         "EU/3/13/1196",
         "Withdrawn",
         "31/10/2013",
         "20/02/2025",
         "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1196"
        ],
        [
         "13",
         null,
         null,
         "amitriptyline",
         "21/06/2022",
         "Treatment of erythromelalgia",
         "EU/3/22/2626",
         "Withdrawn",
         "15/09/2022",
         "20/02/2025",
         "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2626"
        ],
        [
         "14",
         null,
         null,
         "Adeno-associated viral vector serotype 9 containing the human iduronate-2-sulfatase gene",
         "10/08/2015",
         "Treatment of mucopolysaccharidosis type II (Hunter's syndrome)",
         "EU/3/15/1540",
         "Withdrawn",
         "10/08/2015",
         "20/02/2025",
         "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1540"
        ],
        [
         "15",
         null,
         null,
         "Adeno-associated viral vector serotype 9 containing the human N-acetylglucosaminidase-alpha gene",
         "24/01/2013",
         "Treatment of mucopolysaccharidosis type IIIB (Sanfilippo B syndrome)",
         "EU/3/12/1095",
         "Withdrawn",
         "01/03/2013",
         "20/02/2025",
         "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1095"
        ],
        [
         "16",
         null,
         null,
         "Autologous CD34+ cells transduced with a lentiviral vector containing the human RAG1 gene",
         "26/03/2014",
         "Treatment of recombination-activating gene 1 deficient severe combined immunodeficiency",
         "EU/3/14/1257",
         "Positive",
         "07/05/2014",
         "20/02/2025",
         "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1257"
        ],
        [
         "17",
         null,
         null,
         "zopapogene imadenovec",
         "12/01/2024",
         "Treatment of recurrent respiratory papillomatosis",
         "EU/3/23/2887",
         "Positive",
         "11/04/2024",
         "20/02/2025",
         "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2887"
        ],
        [
         "18",
         null,
         null,
         "N-(2-Methoxyethyl)-6-methyl-N-[(3-methyl-2-thienyl)methyl]-2-oxo-1,2-dihydropyridine-4-carboxamide",
         "16/01/2025",
         "Treatment of glycogen storage disease type IV",
         "EU/3/24/3023",
         "Positive",
         "20/02/2025",
         null,
         "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3023"
        ],
        [
         "19",
         null,
         null,
         "volixibat potassium",
         "16/01/2025",
         "Treatment of primary biliary cholangitis",
         "EU/3/24/3017",
         "Positive",
         "20/02/2025",
         null,
         "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3017"
        ],
        [
         "20",
         null,
         null,
         "Allogenic umbilical cord-derived osteoblast cells",
         "16/01/2025",
         "Treatment of non-traumatic osteonecrosis",
         "EU/3/24/3022",
         "Positive",
         "20/02/2025",
         null,
         "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3022"
        ],
        [
         "21",
         null,
         null,
         "Elraglusib",
         "16/01/2025",
         "Treatment of soft tissue sarcoma",
         "EU/3/24/3016",
         "Positive",
         "20/02/2025",
         null,
         "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3016"
        ],
        [
         "22",
         null,
         null,
         "[4-(Methyl-1H-pyrazol-4-yl)-benzyl]-(6[7-(3-pyrrolidin-1-yl-propoxy)-imidazo[1,2-a]pyridin-3-yl]-pyrimidin-4-yl]-amine",
         "16/01/2025",
         "Treatment of gastrointestinal stromal tumours",
         "EU/3/24/3025",
         "Positive",
         "20/02/2025",
         null,
         "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3025"
        ],
        [
         "23",
         null,
         null,
         "Elraglusib",
         "16/01/2025",
         "Treatment of pancreatic cancer",
         "EU/3/24/3015",
         "Positive",
         "20/02/2025",
         null,
         "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3015"
        ],
        [
         "24",
         null,
         null,
         "Alvelestat",
         "16/01/2025",
         "Treatment of congenital alpha-1 antitrypsin deficiency",
         "EU/3/24/3018",
         "Positive",
         "20/02/2025",
         null,
         "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3018"
        ],
        [
         "25",
         null,
         null,
         "Camostat mesilate",
         "16/01/2025",
         "Treatment of chronic pancreatitis",
         "EU/3/24/3021",
         "Positive",
         "20/02/2025",
         null,
         "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3021"
        ],
        [
         "26",
         null,
         null,
         "Humanised monoclonal antibody targeting B-cell maturation antigen conjugated with maleimidocaproyl monomethyl auristatin F",
         "16/10/2017",
         "Treatment of multiple myeloma",
         "EU/3/17/1925",
         "Withdrawn",
         "08/01/2018",
         "19/02/2025",
         "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1925"
        ],
        [
         "27",
         null,
         null,
         "Colistimethate sodium",
         "13/12/2024",
         "Treatment of cystic fibrosis",
         "EU/3/24/2997",
         "Positive",
         "15/01/2025",
         null,
         "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2997"
        ],
        [
         "28",
         null,
         null,
         "tobevibart",
         "13/12/2024",
         "Treatment of hepatitis delta virus infection",
         "EU/3/24/3012",
         "Positive",
         "15/01/2025",
         null,
         "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3012"
        ],
        [
         "29",
         null,
         null,
         "mitapivat sulfate",
         "13/12/2024",
         "Treatment of sickle cell disease",
         "EU/3/24/2999",
         "Positive",
         "15/01/2025",
         null,
         "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2999"
        ],
        [
         "30",
         null,
         null,
         "4-{[(2R,3S,4R,5S)-4-(4-chloro-2-fluoro-phenyl)-3-(3-chloro-2-fluoro-phenyl)-4-cyano-5-(2,2-dimethyl-propyl)-pyrrolidine-2-carbonyl]-amino}-3-methoxy-benzoic acid ",
         "22/08/2014",
         "Treatment of acute myeloid leukaemia",
         "EU/3/14/1328",
         "Withdrawn",
         "02/10/2014",
         "15/01/2025",
         "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1328"
        ],
        [
         "31",
         null,
         null,
         "Losmapimod",
         "24/03/2020",
         "treatment of facioscapulohumeral muscular dystrophy",
         "EU/3/20/2263",
         "Withdrawn",
         "12/08/2020",
         "15/01/2025",
         "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2263"
        ],
        [
         "32",
         null,
         null,
         "3-(3-(3,5-Dimethyl-1H-pyrazol-4-yl)propoxy)-4-fluorobenzoic acid",
         "19/11/2018",
         "Treatment of ATTR amyloidosis",
         "EU/3/18/2081",
         "Withdrawn",
         "19/02/2019",
         "15/01/2025",
         "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2081"
        ],
        [
         "33",
         null,
         null,
         null,
         "15/02/2023",
         "Treatment of Huntington's disease",
         "EU/3/23/2754",
         "Withdrawn",
         "24/01/2024",
         "15/01/2025",
         "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2754"
        ],
        [
         "34",
         null,
         null,
         "isotretinoin",
         "11/10/2022",
         "Treatment of autosomal recessive congenital ichthyosis",
         "EU/3/22/2701",
         "Withdrawn",
         "24/01/2023",
         "15/01/2025",
         "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2701"
        ],
        [
         "35",
         null,
         null,
         "isotretinoin",
         "15/02/2023",
         "Treatment of recessive X-linked ichthyosis",
         "EU/3/23/2760",
         "Withdrawn",
         "24/01/2024",
         "15/01/2025",
         "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2760"
        ],
        [
         "36",
         null,
         null,
         "Omigapil maleate",
         "08/05/2008",
         "Treatment of congenital muscular dystrophy with merosin (laminin alpha 2) deficiency",
         "EU/3/08/544",
         "Withdrawn",
         "29/07/2008",
         "15/01/2025",
         "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-544"
        ],
        [
         "37",
         null,
         null,
         "Omigapil maleate",
         "08/05/2008",
         "Treatment of congenital muscular dystrophy with collagen VI deficiency",
         "EU/3/08/540",
         "Withdrawn",
         "29/07/2008",
         "15/01/2025",
         "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-540"
        ],
        [
         "38",
         null,
         null,
         "propagermanium",
         "19/11/2018",
         "Treatment of focal segmental glomerulosclerosis",
         "EU/3/18/2100",
         "Withdrawn",
         "19/02/2019",
         "15/01/2025",
         "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2100"
        ],
        [
         "39",
         null,
         null,
         "2'-O-4'-C-(S)-Ethyl-P-thioadenylyl-(3'-O->5'-O)-2'-O-4'-C-(S)-ethyl-P-thioguanylyl-(3'-O->5'-O)-2'-O-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-fluoro-P-thioadenylyl-(3'-O->5'-O)-2'-fluoro-P-thiocytidylyl-(3'-O->5'-O)-2'-fluoro-P-thiouridylyl-(3'-O->5'-O)-2'-O-methyl-P-thiouridylyl-(3'-O->5'-O)-2'-O-4'-C-(S)-ethyl-P-thiouridylyl-(3'-O->5'-O)-2'-O-4'-C-(S)-ethyl-adenosine",
         "13/12/2025",
         "Treatment of autosomal dominant polycystic kidney disease",
         "EU/3/24/3009",
         "Positive",
         "15/01/2025",
         null,
         "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3009"
        ],
        [
         "40",
         null,
         null,
         "monepantel",
         "13/12/2024",
         "Treatment of amyotrophic lateral sclerosis",
         "EU/3/24/3004",
         "Positive",
         "15/01/2025",
         null,
         "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3004"
        ],
        [
         "41",
         null,
         null,
         "allogeneic cardiosphere-derived cells",
         "13/12/2025",
         "Treatment of Duchenne muscular dystrophy",
         "EU/3/24/3003",
         "Positive",
         "15/01/2025",
         null,
         "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3003"
        ],
        [
         "42",
         null,
         null,
         "diazoxide choline",
         "13/12/2024",
         "Treatment of glycogen storage disease type I",
         "EU/3/24/3008",
         "Positive",
         "15/01/2025",
         null,
         "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3008-0"
        ],
        [
         "43",
         null,
         null,
         "4-(4-(2-(Diethylamino)ethoxy)phenyl)-1-(4-methoxybenzyl)-1H-1,2,3-triazol-5-amine",
         "13/12/2024",
         "Treatment of neurofibromatosis type 2",
         "EU/3/24/3005",
         "Positive",
         "15/01/2025",
         null,
         "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3005"
        ],
        [
         "44",
         null,
         null,
         "divesiran",
         "13/12/2024",
         "Treatment of polycythaemia vera",
         "EU/3/24/2996",
         "Positive",
         "15/01/2025",
         null,
         "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2996"
        ],
        [
         "45",
         null,
         null,
         "Arsenic trioxide",
         "13/12/2024",
         "Treatment of acute promyelocytic leukaemia",
         "EU/3/24/3014",
         "Positive",
         "14/01/2025",
         null,
         "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3014"
        ],
        [
         "46",
         null,
         null,
         "Davunetide",
         "13/12/2024",
         "Treatment of activity-dependent neuroprotective protein (ADNP) syndrome",
         "EU/3/24/3007",
         "Positive",
         "13/01/2025",
         null,
         "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3007"
        ],
        [
         "47",
         null,
         null,
         "autologous T cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19",
         "13/12/2024",
         "Treatment of myasthenia gravis",
         "EU/3/24/3011",
         "Positive",
         "13/01/2025",
         null,
         "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3011"
        ],
        [
         "48",
         null,
         null,
         "roginolisib",
         "13/12/2024",
         "Treatment of uveal melanoma",
         "EU/3/24/3000",
         "Positive",
         "13/01/2025",
         null,
         "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3000"
        ],
        [
         "49",
         null,
         null,
         "Vosoritide",
         "13/12/2024",
         "Treatment of hypochondroplasia",
         "EU/3/24/2998",
         "Positive",
         "13/01/2025",
         null,
         "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2998"
        ],
        [
         "50",
         null,
         null,
         "Felzartamab",
         "13/12/2024",
         "Treatment of in solid organ transplantation",
         "EU/3/24/3002",
         "Positive",
         "13/01/2025",
         null,
         "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3002"
        ],
        [
         "51",
         null,
         null,
         "votoplam",
         "13/12/2024",
         "Treatment of Huntington's disease",
         "EU/3/24/3001",
         "Positive",
         "13/01/2025",
         null,
         "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3001"
        ],
        [
         "52",
         null,
         null,
         "mRNA encoding Cas9-deaminase, single guide RNA against the human TGM1 gene",
         "13/12/2024",
         "Treatment of autosomal recessive congenital ichthyosis",
         "EU/3/24/3013",
         "Positive",
         "13/01/2025",
         null,
         "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3013"
        ],
        [
         "53",
         null,
         null,
         "elebsiran",
         "13/12/2024",
         "Treatment of hepatitis delta virus infection",
         "EU/3/24/3010",
         "Positive",
         "13/01/2025",
         null,
         "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3010"
        ],
        [
         "54",
         null,
         null,
         "adeno-associated virus serotype 5 containing the human RORA gene",
         "13/12/2024",
         "Treatment of inherited retinal dystrophies due to dysfunction in the ABCA4 gene",
         "EU/3/24/3006",
         "Positive",
         "13/01/2025",
         null,
         "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3006"
        ],
        [
         "55",
         null,
         null,
         "diazoxide choline",
         "13/12/2024",
         "Treatment of glycogen storage disease type I",
         "EU/3/24/3008",
         "Positive",
         "13/01/2025",
         null,
         "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3008"
        ],
        [
         "56",
         null,
         null,
         "[Nle4, D-Phe7]-alfa-melanocyte stimulating hormone (afamelanotide)",
         "08/05/2008",
         "Treatment of erythropoietic protoporphyria",
         "EU/3/08/541",
         "Expired",
         "17/09/2009",
         "09/01/2025",
         "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-541"
        ],
        [
         "57",
         "Emcitate",
         "EMEA/H/C/005220",
         "tiratricol",
         "12/10/2017",
         "Treatment of Allan-Herndon-Dudley syndrome",
         "EU/3/17/1945",
         "Positive",
         "15/01/2018",
         "13/12/2024",
         "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1945"
        ]
       ],
       "shape": {
        "columns": 10,
        "rows": 3061
       }
      },
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th>7</th>\n",
       "      <th>Medicine name</th>\n",
       "      <th>Related EMA product number</th>\n",
       "      <th>Active substance</th>\n",
       "      <th>Date of designation / refusal</th>\n",
       "      <th>Intended use</th>\n",
       "      <th>EU designation number</th>\n",
       "      <th>Status</th>\n",
       "      <th>First published date</th>\n",
       "      <th>Last updated date</th>\n",
       "      <th>Orphan designation URL</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Rilzabrutinib</td>\n",
       "      <td>16/01/2025</td>\n",
       "      <td>Treatment of autoimmune haemolytic anaemia</td>\n",
       "      <td>EU/3/24/3019</td>\n",
       "      <td>Positive</td>\n",
       "      <td>20/02/2025</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Clofutriben</td>\n",
       "      <td>16/01/2025</td>\n",
       "      <td>Treatment of Cushing's syndrome of endogenous ...</td>\n",
       "      <td>EU/3/24/3024</td>\n",
       "      <td>Positive</td>\n",
       "      <td>20/02/2025</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>xevinapant</td>\n",
       "      <td>11/11/2015</td>\n",
       "      <td>Treatment of ovarian cancer</td>\n",
       "      <td>EU/3/15/1576</td>\n",
       "      <td>Withdrawn</td>\n",
       "      <td>06/01/2016</td>\n",
       "      <td>20/02/2025</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Adeno-associated virus serotype 5 vector encod...</td>\n",
       "      <td>10/11/2022</td>\n",
       "      <td>Treatment of hereditary angioedema</td>\n",
       "      <td>EU/3/22/2722</td>\n",
       "      <td>Withdrawn</td>\n",
       "      <td>23/01/2023</td>\n",
       "      <td>20/02/2025</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Autologous CD34+ cells transfected with lentiv...</td>\n",
       "      <td>07/10/2013</td>\n",
       "      <td>Treatment of Wiskott-Aldrich syndrome</td>\n",
       "      <td>EU/3/13/1196</td>\n",
       "      <td>Withdrawn</td>\n",
       "      <td>31/10/2013</td>\n",
       "      <td>20/02/2025</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3064</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Thymalfasin</td>\n",
       "      <td>30/07/2002</td>\n",
       "      <td>Treatment of hepatocellular carcinoma</td>\n",
       "      <td>EU/3/02/110</td>\n",
       "      <td>Positive</td>\n",
       "      <td>08/01/2003</td>\n",
       "      <td>08/01/2003</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3065</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>chlorproguanil hydrochloride;dapsone</td>\n",
       "      <td>26/07/2002</td>\n",
       "      <td>Treatment of acute uncomplicated plasmodium fa...</td>\n",
       "      <td>-</td>\n",
       "      <td>Negative</td>\n",
       "      <td>08/01/2003</td>\n",
       "      <td>08/01/2003</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3066</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Autologous Renal Cell Tumour Vaccine</td>\n",
       "      <td>21/10/2002</td>\n",
       "      <td>Treatment of renal-cell carcinoma</td>\n",
       "      <td>EU/3/02/116</td>\n",
       "      <td>Positive</td>\n",
       "      <td>08/01/2003</td>\n",
       "      <td>08/01/2003</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3067</th>\n",
       "      <td>Prohippur</td>\n",
       "      <td>EMEA/H/C/004150</td>\n",
       "      <td>Benzoic acid, sodium salt</td>\n",
       "      <td>11/09/2002</td>\n",
       "      <td>Treatment of non-ketotic hyperglycinaemia</td>\n",
       "      <td>EU/3/02/111</td>\n",
       "      <td>Positive</td>\n",
       "      <td>08/01/2003</td>\n",
       "      <td>08/01/2003</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3068</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Recombinant glycoprotein gp350 of Epstein-Barr...</td>\n",
       "      <td>22/10/2002</td>\n",
       "      <td>Prevention of post-transplantation lympho-prol...</td>\n",
       "      <td>EU/3/02/118</td>\n",
       "      <td>Positive</td>\n",
       "      <td>17/12/2002</td>\n",
       "      <td>17/12/2002</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/o...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>3061 rows × 10 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "7    Medicine name Related EMA product number  \\\n",
       "8              NaN                        NaN   \n",
       "9              NaN                        NaN   \n",
       "10             NaN                        NaN   \n",
       "11             NaN                        NaN   \n",
       "12             NaN                        NaN   \n",
       "...            ...                        ...   \n",
       "3064           NaN                        NaN   \n",
       "3065           NaN                        NaN   \n",
       "3066           NaN                        NaN   \n",
       "3067     Prohippur            EMEA/H/C/004150   \n",
       "3068           NaN                        NaN   \n",
       "\n",
       "7                                      Active substance  \\\n",
       "8                                         Rilzabrutinib   \n",
       "9                                           Clofutriben   \n",
       "10                                           xevinapant   \n",
       "11    Adeno-associated virus serotype 5 vector encod...   \n",
       "12    Autologous CD34+ cells transfected with lentiv...   \n",
       "...                                                 ...   \n",
       "3064                                        Thymalfasin   \n",
       "3065               chlorproguanil hydrochloride;dapsone   \n",
       "3066               Autologous Renal Cell Tumour Vaccine   \n",
       "3067                          Benzoic acid, sodium salt   \n",
       "3068  Recombinant glycoprotein gp350 of Epstein-Barr...   \n",
       "\n",
       "7    Date of designation / refusal  \\\n",
       "8                       16/01/2025   \n",
       "9                       16/01/2025   \n",
       "10                      11/11/2015   \n",
       "11                      10/11/2022   \n",
       "12                      07/10/2013   \n",
       "...                            ...   \n",
       "3064                    30/07/2002   \n",
       "3065                    26/07/2002   \n",
       "3066                    21/10/2002   \n",
       "3067                    11/09/2002   \n",
       "3068                    22/10/2002   \n",
       "\n",
       "7                                          Intended use EU designation number  \\\n",
       "8            Treatment of autoimmune haemolytic anaemia          EU/3/24/3019   \n",
       "9     Treatment of Cushing's syndrome of endogenous ...          EU/3/24/3024   \n",
       "10                          Treatment of ovarian cancer          EU/3/15/1576   \n",
       "11                   Treatment of hereditary angioedema          EU/3/22/2722   \n",
       "12                Treatment of Wiskott-Aldrich syndrome          EU/3/13/1196   \n",
       "...                                                 ...                   ...   \n",
       "3064              Treatment of hepatocellular carcinoma           EU/3/02/110   \n",
       "3065  Treatment of acute uncomplicated plasmodium fa...                     -   \n",
       "3066                  Treatment of renal-cell carcinoma           EU/3/02/116   \n",
       "3067          Treatment of non-ketotic hyperglycinaemia           EU/3/02/111   \n",
       "3068  Prevention of post-transplantation lympho-prol...           EU/3/02/118   \n",
       "\n",
       "7        Status First published date Last updated date  \\\n",
       "8      Positive           20/02/2025               NaN   \n",
       "9      Positive           20/02/2025               NaN   \n",
       "10    Withdrawn           06/01/2016        20/02/2025   \n",
       "11    Withdrawn           23/01/2023        20/02/2025   \n",
       "12    Withdrawn           31/10/2013        20/02/2025   \n",
       "...         ...                  ...               ...   \n",
       "3064   Positive           08/01/2003        08/01/2003   \n",
       "3065   Negative           08/01/2003        08/01/2003   \n",
       "3066   Positive           08/01/2003        08/01/2003   \n",
       "3067   Positive           08/01/2003        08/01/2003   \n",
       "3068   Positive           17/12/2002        17/12/2002   \n",
       "\n",
       "7                                Orphan designation URL  \n",
       "8     https://www.ema.europa.eu/en/medicines/human/o...  \n",
       "9     https://www.ema.europa.eu/en/medicines/human/o...  \n",
       "10    https://www.ema.europa.eu/en/medicines/human/o...  \n",
       "11    https://www.ema.europa.eu/en/medicines/human/o...  \n",
       "12    https://www.ema.europa.eu/en/medicines/human/o...  \n",
       "...                                                 ...  \n",
       "3064  https://www.ema.europa.eu/en/medicines/human/o...  \n",
       "3065  https://www.ema.europa.eu/en/medicines/human/o...  \n",
       "3066  https://www.ema.europa.eu/en/medicines/human/o...  \n",
       "3067  https://www.ema.europa.eu/en/medicines/human/o...  \n",
       "3068  https://www.ema.europa.eu/en/medicines/human/o...  \n",
       "\n",
       "[3061 rows x 10 columns]"
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import pandas as pd\n",
    "\n",
    "df_orphan_drugs = pd.read_excel(r\"C:\\Users\\maria\\ITAcademy\\Sprint 10 - Pràctica final\\Data\\medicines_output_orphan_designations_en.xlsx\")\n",
    "df_orphan_drugs = df_orphan_drugs[7:]\n",
    "\n",
    "df_orphan_drugs.columns = df_orphan_drugs.iloc[0]  # header\n",
    "df_orphan_drugs = df_orphan_drugs[1:]  # borrar la 1ª fila\n",
    "\n",
    "#df_orphan_drugs.to_csv(r\"C:\\Users\\maria\\ITAcademy\\Sprint 10 - Pràctica final\\Data\\df_orphan_drugs.csv\", index=False)\n",
    "df_orphan_drugs"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "5295cfbd",
   "metadata": {},
   "source": [
    "- Falta limpiar bien el df.\n",
    "- Se podría buscar un dataset que nos permita relacionar los medicamentos huérfanos con las enfermedades (En Kaggle hay uno: https://www.kaggle.com/datasets/rajendarreddie/fda-orphan-drugs-data)\n"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.13.2"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
